Adina Turcu is an Endocrinology/Metabolic physician affiliated with University of Michigan. OpenAlex indexes 243 publications with 4,958 citations (h-index 41).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
24 Frank Lloyd Wright Dr
Lobby C Suite 1300
Ann Arbor, MI 481059484
Telephone
734-647-5871Registry record last updated 21 Jun 2019.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- AstraZeneca UK LimitedProgram year20241 payment
- Bayer HealthCare Pharmaceuticals Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
46.7%Corticosteroid46.7%Hydrocortisone100%Part D≥11 patientsHormonal (systemic)
28.9%l-Thyroxine28.9%Levothyroxine Sodium100%Part D<11 patientsCardiovascular
24.4%Aldosterone antagonist (MRA)24.4%Spironolactone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- 11-Oxyandrogens and Aging: Health Implications
University of Michigan at Ann Arbor
FY2026$564,488R01AG080516 - Primary Aldosteronism Subtypes: Pathophysiology and Steroid Signatures
University of Michigan at Ann Arbor
FY2025$676,177R01HL155834 - 11-Oxyandrogens and Aging: Health Implications
University of Michigan at Ann Arbor
FY2025$553,199R01AG080516
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort
The Lancet Diabetes & Endocrinology
2025 - The Spectrum of Dysregulated Aldosterone Production: An International Human Physiology Study
The Journal of Clinical Endocrinology & Metabolism
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”